ORPHA:698043
Fibromuscular dysplasia of the renal arteries
Also known as: Renal FMD · Renal artery fibromuscular dysplasia
How rare: How common this is has not been clearly measured.
Is anyone studying this?
335
335 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
335 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
152 in the last 10 years · low confidence
Is a treatment being tested?
1
trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting.
Data as of 26 July 2026
1 interventional trial — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 65.3th percentile).
low confidence · 65.3th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
1,094
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Persu A11 papers · 2026
Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Papers in Europe PMC - 02
- 03Januszewicz A8 papers · 2022
Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
Papers in Europe PMC - 04Adlam D6 papers · 2022
Department of Cardiovascular Sciences, University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
Papers in Europe PMC - 05Gornik HL6 papers · 2022
1 Division of Cardiovascular Medicine, University Hospitals Cleveland Medical Center and UH Harrington Heart and Vascular Institute, Cleveland, OH, USA.
Papers in Europe PMC - 06Jeunemaitre X6 papers · 2019
17 APHP, Department of Genetics and Centre for Rare Vascular Diseases, Hôpital Européen Georges Pompidou, Paris, France.
Papers in Europe PMC - 07Olin JW6 papers · 2022
Zena and Michael A Wiener Cardiovascular Institute & the Marie-Josée and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA jeffrey.olin@mountsinai.org.
Papers in Europe PMC - 08Pappaccogli M6 papers · 2024
Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Papers in Europe PMC - 09Prejbisz A6 papers · 2022
Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
Papers in Europe PMC - 10Touzé E6 papers · 2026
Department of Neurology, Paris Descartes University, Sainte-Anne Hospital, 1, rue Cabanis, 75014 Paris, France; Department of Neurology, University of Caen Basse-Normandie, CHU Côte de Nacre, 14000 Caen, France. Electronic address: emmanuel.touze@unicaen.fr.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Fibromuscular dysplasia of the renal arteries" OR "Renal FMD" OR "Renal artery fibromuscular dysplasia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Fibromuscular dysplasia of the renal arteries" OR "Fibromuscular dysplasia of renal arteries" OR "Renal FMD" OR "Renal artery fibromuscular dysplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
0Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low